Swiss drugmaker Novartis will keep making medicines for malaria and leprosy, even if it does not get orders as normal amid ...

Novartis has agreed to buy Regulus Therapeutics for up to $1.7 billion, giving the Swiss drugmaker access to an experimental drug to treat a life-threatening kidney disease. Under the deal terms, ...

New Novartis data at ASCO and EHA showcase momentum of pioneering portfolio with promising pipeline: Basel Saturday, May 17, 2025, 11:00 Hrs [IST] Novartis will present data from ...

GlobalData analysts have tipped the global market for genomic therapies to balloon to almost $90 billion by 2030, driven by ...

Incyte said it agreed to pay Novartis $280 million to settle the disputed royalties on U.S. sales of blood-cancer treatment Jakafi through Dec. 31. The parties also agreed to reduce by 50% the royalty ...

PTC Therapeutics reported a phase 2 win for its Novartis-partne | PTC Therapeutics reported a phase 2 win for its ...

Just before the May 5 trial date set for Novartis and Incyte to finally hash out their Jakafi royalty dispute in court, the ...

At the intersection of radiation and precision, Novartis, Bayer, AstraZeneca and more hope to cash in on a ...

LONDON (Reuters) -Swiss drugmaker Novartis will keep making medicines for malaria and leprosy, even if it does not get orders as normal amid the global health funding crunch, its president of ...

Headquartered in Basel, Novartis (NVS) is a Medical stock that has seen a price change of 17.45% so far this year. Currently paying a dividend of $2.6 per share, the company has a dividend yield of ...